# A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058

> **NCT05803850** · PHASE1 · COMPLETED · sponsor: **Guangzhou Henovcom Bioscience Co. Ltd.** · enrollment: 32 (actual)

## Conditions studied

- IPF

## Interventions

- **DRUG:** HNC1058 Capsules

## Key facts

- **NCT ID:** NCT05803850
- **Lead sponsor:** Guangzhou Henovcom Bioscience Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-28
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-03-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803850, "A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05803850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*